Ahpra registration PHY0002298174
How these guides are written and reviewed →
Peripheral arterial disease is narrowing of the arteries that supply the legs, reducing blood flow to the muscles. The classic symptom is a cramping leg pain on walking that eases with rest — sometimes called "angina of the legs". It is a warning sign of artery disease elsewhere, so managing risk factors (especially stopping smoking) protects the heart and brain too. A supervised walking programme is one of the most effective treatments, alongside medicines and sometimes procedures. This page explains the condition and how it is managed.
Peripheral arterial disease is the systemic vascular consequence of the same atherosclerotic process that causes coronary and cerebrovascular disease, and it is consistently under-diagnosed and under-treated in Australia. Supervised exercise therapy is established as first-line treatment for intermittent claudication, with evidence equivalent to and complementary to revascularisation.
Definition
Peripheral arterial disease (PAD) refers to atherosclerotic narrowing of the arteries supplying the lower limbs (and, by extension, the carotid, renal, mesenteric, and upper limb arteries). Clinical presentations span asymptomatic disease, intermittent claudication, chronic limb-threatening ischaemia (CLTI), and acute limb ischaemia.
Pathophysiology
PAD reflects systemic atherosclerosis with the same drivers as coronary disease — endothelial dysfunction, lipid deposition, inflammation, and progressive luminal narrowing. The lower limb circulation is particularly vulnerable due to length and pressure gradients. Symptoms occur when distal perfusion fails to meet metabolic demand, classically during exertion.
Co-morbidities
PAD is a marker for polyvascular disease; the majority of patients have concurrent coronary, cerebrovascular, or renal artery disease. Diabetes, smoking, hypertension, dyslipidaemia, and chronic kidney disease are the dominant clustering co-morbidities.
Prevalence
PAD affects approximately 10% of Australian adults aged > 60 and rises sharply with age and diabetes. A substantial majority of cases remain undiagnosed, with classic claudication symptoms reported by only a minority of those with measurable disease on ABI testing.
Causes and risk factors
Modifiable: smoking (the single strongest risk factor; relative risk 2–6), diabetes (particularly for distal disease and CLTI), hypertension, dyslipidaemia, obesity, physical inactivity.
Non-modifiable: age, male sex, Aboriginal and Torres Strait Islander identity, family history.
Symptoms
Intermittent claudication: cramping, aching, or fatigue in the calf, thigh, or buttock that is reproducibly provoked by walking and relieved within minutes of rest. Pattern of involvement reflects the arterial level (calf — femoropopliteal; thigh and buttock — aortoiliac).
CLTI: rest pain (particularly nocturnal, partly relieved by limb dependency), tissue loss (non-healing ulcer, gangrene), and audible "diabetic" or neuropathic descriptors may mask classic ischaemic features. CLTI is a limb- and life-threatening emergency.
Acute limb ischaemia (the "six Ps": pain, pallor, pulselessness, paraesthesia, paralysis, perishing cold) requires immediate vascular assessment.
Diagnosis
Why diagnosis matters
PAD is a powerful marker of systemic atherosclerosis with mortality risk comparable to established coronary disease. Diagnosis enables risk factor modification, supervised exercise therapy, and timely vascular intervention for CLTI to prevent amputation.1
How the diagnosis is made
Resting ankle-brachial index (ABI) is the principal screening test, with ABI < 0.9 supporting diagnosis. Toe-brachial index is used in patients with calcified, incompressible arteries (diabetes, advanced CKD). Exercise ABI is used where rest ABI is normal but symptoms are typical.
Imaging
Duplex ultrasound is the first-line imaging modality. CT angiography and MR angiography are used for procedural planning. Catheter-based angiography is reserved for those undergoing intervention.
Global vascular assessment
New PAD diagnosis warrants assessment of cardiovascular risk factors and screening for concurrent vascular disease where clinically indicated. ECG, lipid profile, fasting glucose or HbA1c, renal function, and (where symptoms suggest) carotid duplex.
Management
Treatment goals
Twin goals are limb-focused (reduce claudication, prevent CLTI and amputation, improve walking distance and quality of life) and systemic (reduce cardiovascular events and death). Most patients derive larger absolute prognostic benefit from systemic risk factor modification than from limb-directed therapy alone.
Supervised exercise therapy — first-line for claudication
Supervised exercise therapy is established as first-line treatment for intermittent claudication in Australian and international vascular guidelines. The standard prescription is at least 3 sessions per week for 12 weeks, with sessions of 30–60 minutes of intermittent walking to near-maximal claudication pain, alternating with rest. Outcomes are at least equivalent to endovascular revascularisation for many patients.2,3,4
Home-based structured exercise with regular clinician review and behavioural support is an established alternative where supervised programmes are not accessible, and is particularly relevant for patients in regional and remote Central Queensland.
Risk factor modification
Smoking cessation is the single most important intervention and substantially modifies disease trajectory. Antiplatelet therapy (aspirin 100 mg or clopidogrel 75 mg). High-intensity statin (with LDL-C target as for other established CVD). Blood pressure control. Diabetes optimisation including SGLT2 inhibitors and GLP-1 receptor agonists where indicated.
Pharmacological adjuncts for claudication
Cilostazol is the only agent with consistent evidence for improving walking distance in claudication and is PBS-listed in Australia under specific criteria. Contraindicated in heart failure. Naftidrofuryl and pentoxifylline have modest evidence but are not widely used.
Low-dose rivaroxaban 2.5 mg bd in addition to aspirin (COMPASS-PAD regimen) reduces major adverse limb and cardiovascular events in selected high-risk patients and is increasingly used.
Revascularisation
Endovascular therapy (angioplasty with or without stenting) or open bypass surgery is reserved for lifestyle-limiting claudication refractory to optimal exercise and pharmacological therapy, and for chronic limb-threatening ischaemia. Choice of approach is based on anatomy, comorbidity, patient goals, and vascular surgical assessment.
Identifying CLTI and acute limb ischaemia
CLTI (rest pain, tissue loss) requires urgent vascular review (days, not weeks). Acute limb ischaemia is a vascular emergency — immediate referral, anticoagulation, and revascularisation within hours.5
Medications
Antithrombotic therapy
Aspirin 100 mg daily or clopidogrel 75 mg daily for symptomatic PAD. COMPASS-PAD regimen (aspirin plus rivaroxaban 2.5 mg bd) in selected patients without high bleeding risk.6,7
Lipid-lowering therapy
High-intensity statin (atorvastatin 40–80 mg, rosuvastatin 20–40 mg) with ezetimibe and PCSK9 inhibitor as required to reach LDL-C target. Lipid-lowering therapy reduces both cardiovascular events and limb events including amputation.
Cilostazol
Phosphodiesterase-3 inhibitor with antiplatelet and vasodilator effects. Modest but consistent improvement in walking distance over 3–6 months. Side effects: headache, palpitations, diarrhoea. Contraindicated in heart failure.
Diabetes therapy
SGLT2 inhibitors and GLP-1 receptor agonists are preferred where diabetes coexists, with attention to genitourinary infection risk in patients with limb ulceration.
Multi-system manifestations
Polyvascular disease
Most patients with PAD have concurrent coronary or cerebrovascular disease. Routine screening for asymptomatic CAD is not recommended, but symptom-directed assessment is part of comprehensive care.
Foot care and tissue integrity
Daily foot inspection, well-fitting footwear, regular podiatry, prompt attention to minor injuries, and avoidance of barefoot walking are core to preventing ulceration and amputation, particularly with concurrent diabetes.
Erectile dysfunction
Erectile dysfunction is common in PAD (shared vascular pathology) and frequently under-discussed. Specific screening and treatment improve quality of life and may serve as a sentinel marker for broader vascular disease.
Living with PAD
Exercise — the cornerstone
Engagement in regular structured walking exercise is the single intervention with the greatest functional benefit. Patients should be reassured that walking through claudication pain is safe, does not cause damage, and is therapeutic. Pole walking, treadmill, and pain-paced overground walking are all effective.8,9
Smoking cessation
Smoking cessation halts disease progression and substantially reduces cardiovascular events. All available pharmacological and behavioural supports should be offered (NRT, varenicline, bupropion, Quitline).
Foot care
Daily inspection, podiatry, appropriate footwear, prompt review of minor injuries, and avoidance of extreme temperatures. This is particularly critical with concurrent diabetes or sensory neuropathy.
Travel
Long periods of immobility (long-haul flights, prolonged driving) should be broken up with walking; graduated compression should not be used in PAD without specialist input as it may worsen perfusion.
Prognosis
For asymptomatic and claudicant PAD with optimal management, limb prognosis is good and most patients do not progress to CLTI. Cardiovascular event risk remains high and is the principal determinant of survival.
Psychological dimension
Fear of amputation, frustration with mobility limitation, depression, and reduced social participation are common and often unaddressed. Pulmonary and cardiac rehabilitation programmes increasingly incorporate PAD patients with structured exercise and behavioural support.
Role of the physiotherapist
Supervised exercise therapy is first-line treatment for claudication, and the physiotherapist leads it — structured walking to near-maximal pain, progressed over time — alongside cardiovascular risk-factor and lifestyle support, improving walking distance and quality of life.
Warning signs
Part 1 · References
- Gornik HL, Aronow HD, Goodney PP, et al. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease. Circulation 2024;149(24):e1313–e1410.
- Lane R, Harwood A, Watson L, Leng GC. Exercise for intermittent claudication. Cochrane Database Syst Rev 2017;(12):CD000990.
- Murphy TP, Cutlip DE, Regensteiner JG, et al. Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease (CLEVER). Circulation 2012;125(1):130–139.
- Parmenter BJ, Dieberg G, Smart NA. Exercise training for management of peripheral arterial disease: a systematic review and meta-analysis. Sports Med 2015;45(2):231–244.
- Conte MS, Bradbury AW, Kolh P, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. Eur J Vasc Endovasc Surg 2019;58(1S):S1–S109.
- Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease (COMPASS): an international, randomised, double-blind, placebo-controlled trial. Lancet 2018;391(10117):219–229.
- Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in peripheral artery disease after revascularization (VOYAGER PAD). N Engl J Med 2020;382(21):1994–2004.
- McDermott MM, Spring B, Tian L, et al. Effect of low-intensity vs high-intensity home-based walking exercise on walk distance in patients with peripheral artery disease (LITE): a randomized clinical trial. JAMA 2021;325(13):1266–1276.
- McDermott MM, Liu K, Guralnik JM, et al. Home-based walking exercise intervention in peripheral artery disease (GOALS): a randomized clinical trial. JAMA 2013;310(1):57–65.
References are numbered in citation order (Vancouver/BMJ style) and were current at the time of writing. Guidelines are living documents — verify against the latest version before clinical use.
Supervised exercise, breathing technique and self-management education are the mainstay of cardiorespiratory physiotherapy for this condition.
Clinical evidence
Part 1 covers the same condition without the technical detail. What follows is the evidence base behind it, written for clinicians — the literature, the reasoning and the gaps.
For clinicians: this summary supports clinical reasoning and is not a protocol. Check current guidelines and local policy before applying it, and read it alongside the key references and guidelines directory.
Framing. Peripheral arterial disease is both a limb problem and a marker of systemic atherosclerosis with high cardiovascular mortality, and the guidelines are unusually clear about the first-line treatment for claudication: supervised exercise therapy, alongside risk-factor modification, before revascularisation is considered for symptoms.1 That makes this one of the strongest cases in vascular medicine for physiotherapy as primary therapy rather than adjunct.
Exercise as first-line therapy
- Supervised exercise substantially improves walking distance in intermittent claudication — the Cochrane review reports large increases in maximal and pain-free walking distance versus usual care, with benefit sustained up to two years.2
- CLEVER showed supervised exercise produced greater treadmill walking improvement than stenting in aortoiliac disease, while stenting gave better patient-reported quality of life — evidence that exercise is not a lesser option.3
- Intensity matters more than volume. In the LITE trial, high-intensity home-based walking that induced ischaemic leg symptoms improved six-minute walk distance, whereas low-intensity walking without symptoms did not — and was no better than control.4
- Structured home-based programmes with coaching and monitoring improve walking performance when they include accountability; unstructured "advice to walk" does not.5
- Alternative modalities — arm ergometry, cycling, progressive resistance training — improve walking capacity in patients who cannot tolerate walking programmes, which matters in comorbid and arthritic populations.2,6
Medical and revascularisation context
- Best medical therapy includes high-intensity statin, antiplatelet therapy, blood-pressure and glycaemic control, and smoking cessation; PAD confers cardiovascular risk comparable to established coronary disease.1,7
- Low-dose rivaroxaban plus aspirin reduced major adverse cardiovascular and limb events in PAD (COMPASS, VOYAGER PAD), at the cost of more bleeding.7,8
- Chronic limb-threatening ischaemia is a different disease: rest pain, tissue loss or gangrene requires urgent revascularisation assessment and wound care, not an exercise programme.1,9
- Diagnosis rests on ankle–brachial index, with toe pressures or duplex in diabetes and calcified vessels, where ABI can be falsely normal.1
Physiotherapy implications
- Prescribe walking to moderate-to-severe claudication pain, rest until it resolves, then repeat — typically 30–45 minutes of intermittent walking, three times weekly, for at least 12 weeks. Pain avoidance is the commonest reason a programme fails.2,4
- Warn the patient in advance that provoking pain is the treatment, and explain why — without that explanation adherence collapses.
- Use supervision where available, structure where it is not: a home programme needs a schedule, a log, a target and follow-up contact to work.5
- Screen the feet every session in diabetic and CLTI patients: any ulcer, discolouration, rest pain or non-healing wound stops the exercise conversation and starts an urgent referral.9
- Deliver smoking cessation actively — it is the highest-value intervention for limb and life outcome in this disease and is frequently reduced to a single line of advice.1
- Screen for coexisting coronary disease before high-intensity work: many patients have silent coronary disease, and exertional chest pain or disproportionate breathlessness needs cardiology assessment.7
- Add resistance and balance training, since these patients are typically older, sedentary, sarcopenic and at fall risk, and leg strength contributes to walking capacity.6
Clinical reasoning
- Distinguish claudication (reproducible, exercise-onset, relieved by standing rest within minutes) from spinal stenosis (relieved by flexion or sitting, variable distance) and from venous or musculoskeletal pain — the treatments diverge completely.
- Rest pain, night pain relieved by hanging the leg out of bed, or tissue loss is limb-threatening and urgent.9
- Failure to improve after 12 weeks of genuinely painful walking is a reason to re-refer, not to extend the programme indefinitely.
- Frame the programme around cardiovascular mortality as well as walking distance — the legs are the presenting complaint, not the whole problem.7
Evidence gaps
- The optimal balance of intensity, frequency and duration — and how much pain is enough — is still being defined.4
- Long-term maintenance after supervised programmes end is poorly studied, and gains attenuate.2
- Whether exercise therapy alters limb-event or mortality outcomes, as opposed to walking capacity, is not established.
- Evidence for exercise after revascularisation, and its ideal timing, remains thin.8
References for the clinical evidence summary
- Gornik HL, Aronow HD, Goodney PP, et al. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease. Circulation 2024;149(24):e1313–e1410.
- Lane R, Harwood A, Watson L, Leng GC. Exercise for intermittent claudication. Cochrane Database Syst Rev 2017;(12):CD000990.
- Murphy TP, Cutlip DE, Regensteiner JG, et al. Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease (CLEVER). Circulation 2012;125(1):130–139.
- McDermott MM, Spring B, Tian L, et al. Effect of low-intensity vs high-intensity home-based walking exercise on walk distance in patients with peripheral artery disease (LITE): a randomized clinical trial. JAMA 2021;325(13):1266–1276.
- McDermott MM, Liu K, Guralnik JM, et al. Home-based walking exercise intervention in peripheral artery disease (GOALS): a randomized clinical trial. JAMA 2013;310(1):57–65.
- Parmenter BJ, Dieberg G, Smart NA. Exercise training for management of peripheral arterial disease: a systematic review and meta-analysis. Sports Med 2015;45(2):231–244.
- Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease (COMPASS): an international, randomised, double-blind, placebo-controlled trial. Lancet 2018;391(10117):219–229.
- Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in peripheral artery disease after revascularization (VOYAGER PAD). N Engl J Med 2020;382(21):1994–2004.
- Conte MS, Bradbury AW, Kolh P, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. Eur J Vasc Endovasc Surg 2019;58(1S):S1–S109.
Corrections: If something on this page is wrong, out of date or unclear, we want to know. Email reception@inspireclinic.au with the page name and what you believe is incorrect. Substantive corrections are made promptly, and the guide’s version and last-updated date are changed to reflect it.